Kymera Investor Day Presentation Deck
Tumor Volume (mm³)
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0
KYMERA
KT-413 Has Strong Activity in Combination
in MYD88MT OCI-Ly10 Xenografts
with BTK Inhibitor
Vehicle
Ibrutinib, 12.5 mg/kg, PO, QD x 21
KT-413,3 mg/kg, IV, D1, 2, 15, 16
Ibrutinib + KT-413
5
10 15 20 25 30
Days after the Start of Treatment
• KT-413 administered on
intermittent schedules leads
to strong regressions in
combination with the BTK
inhibitor Ibrutinib
35 40
Tumor Volume (mm³)
©2021 KYMERA THERAPEUTICS, INC.
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0
with BCL-2 Inhibitor
Vehicle, PO, QD x 21
Venetoclax, 50 mg/kg, PO, QD x 21
KT-413,3 mg/kg, IV, D1, 2, 15, 16
Venetoclax + KT-413
5 10 15 20 25 30 35 40
Days after the Start of Treatment
• KT-413 administered on
intermittent schedules leads
to deep and durable
regressions in combination
with the BCL-2 inhibitor,
Venetoclax
Tumor Volume (mm³)
KYMERA R&D DAY - December 16th, 2021
3000
2500
2000
1500
1000
500-
0
10
with Rituxan
Data support potential for KT-413 in combination in earlier lines of therapy
Vehicle
Rituxan, 10 mg/kg, IP, BIW
KT-413,3 mg/kg, IV, D1,2,8,22,23
Rituxan + KT-413
20 30 40 50 60 70
Days after the Start of Treatment
80
• KT-413 administered on
intermittent schedules leads
to deep and durable
regressions in combination
with Rituxan
90
PAGE 54View entire presentation